View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
October 8, 2021

Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial

In a Phase IIb trial, remibrutinib achieved statistically significant, dose-response improvement versus placebo.

By Reynald Castañeda

Novartis’s remibrutinib saw a six-point jump in its Phase Transition Success Rate (PTSR) in chronic, spontaneous urticaria (CSU) after positive Phase IIb data was reported. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. Results from the 311-patient Phase IIb trial (NCT03926611) were revealed on 30 September. Remibrutinib’s PTSR was updated on 4 October and now stands at 55%.

Urticaria is more commonly known as hives. In the study, remibrutinib achieved statistically significant, dose-response improvement versus placebo in the primary endpoint change from baseline in the weekly Urticaria Activity Score (UAS7) at week 4. The trial recruited patients who had inadequate symptom control with antihistamines. Remibrutinib is an oral BTK inhibitor.

Remibrutinib also had a 3-point increase in its Likelihood of Approval (LoA) to 31% on the back of positive Phase IIb data. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Click here for this week’s regulatory roundup

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU